Back to top
more

Aclaris Therapeutics (ACRS)

(Delayed Data from NSDQ)

$1.91 USD

1.91
2,043,968

-0.04 (-2.05%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $1.88 -0.03 (-1.57%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (104 out of 245)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.

Zacks Equity Research

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

by Zacks Equity Research

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study

by Zacks Equity Research

Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

Zacks Equity Research

ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 400% and 6.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 6.67% and 8.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?

by Zacks Equity Research

Calliditas Therapeutics AB Sponsored ADR (CALT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 4.55% and 36.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zoetis (ZTS) Q1 Earnings Top Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 3.15% and 0.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Philips (PHG) Showcases New AI-Based Solutions at the RSNA

by Zacks Equity Research

Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Philips (PHG) Expands AI Portfolio With SmartSpeed Solution

by Zacks Equity Research

Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.

Zacks Equity Research

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Zacks Equity Research

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 141% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 179.1% in Aclaris (ACRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.